相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current and emerging biologic therapies for triple negative breast cancer
Saba S. Shaikh et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2022)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints
Shawn C. Chafe et al.
CANCERS (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
Guoxuan Gao et al.
BMC CANCER (2020)
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
Paula Gonzalez-Ericsson et al.
JOURNAL OF PATHOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer
Ashenafi Bulle et al.
TRANSLATIONAL ONCOLOGY (2020)
Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer
Xin Zhang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals
Min Tang et al.
PROSTATE (2020)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations
Athanasios Pouptsis et al.
FRONTIERS IN ONCOLOGY (2020)
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Mariya Rozenblit et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment
Xing-Yu Mu et al.
MOLECULAR IMMUNOLOGY (2019)
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial
Leonie Voorwerk et al.
NATURE MEDICINE (2019)
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
James W. Opzoomer et al.
FRONTIERS IN IMMUNOLOGY (2019)
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors
Li Zhu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Gemcitabine nanoparticles promote antitumor immunity against melanoma
Yuan Zhang et al.
BIOMATERIALS (2019)
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial
Karama Asleh et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Immune gene expression and response to chemotherapy in advanced breast cancer
Theodoros Foukakis et al.
BRITISH JOURNAL OF CANCER (2018)
Docetaxel promotes the generation of anti-tumorigenic human macrophages
Camilla Rydberg Millrud et al.
EXPERIMENTAL CELL RESEARCH (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Chemotherapy induces enrichment of CD47+/CD73+/PDL1+ immune evasive triple-negative breast cancer cells
Debangshu Samanta et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis
Willemijne A. M. E. Schrijver et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
A. M. Gravett et al.
ONCOIMMUNOLOGY (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
Immune characterization of breast cancer metastases: prognostic implications
Maria Vittoria Dieci et al.
RESPIRATORY RESEARCH (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
Samantha Burugu et al.
BREAST CANCER (2017)
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer A Secondary Analysis of a Randomized Clinical Trial
Shuzhen Liu et al.
JAMA ONCOLOGY (2017)
LAG-3+tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+tumors
S. Burugu et al.
ANNALS OF ONCOLOGY (2017)
Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer
Zenobia D'Costa et al.
CANCER RESEARCH (2017)
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer
Shigehiro Koganemaru et al.
CANCER SCIENCE (2017)
Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+Tregs : a systematic review and meta-analysis
Jiafeng Shou et al.
BMC CANCER (2016)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Carsten Denkert et al.
MODERN PATHOLOGY (2016)
Clinical significance of tumor-infiltrating lymphocytes in breast cancer
Sasha E. Stanton et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
Matthew D. Burstein et al.
CLINICAL CANCER RESEARCH (2015)
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
Charlotte L. T. Jorgensen et al.
ACTA ONCOLOGICA (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Prognostic significance of FOXP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2014)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
Dorte L. Nielsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
Krithika N. Kodumudi et al.
CLINICAL CANCER RESEARCH (2010)
Prognostic significance of macrophage infiltration in leiomyosarcomas
Cheng-Han Lee et al.
CLINICAL CANCER RESEARCH (2008)
Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2008)
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival
Maggie C. U. Cheang et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F Ghiringhelli et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
分享论文
